BR112014015178A2 - uso de pelo menos um composto - Google Patents

uso de pelo menos um composto

Info

Publication number
BR112014015178A2
BR112014015178A2 BR112014015178A BR112014015178A BR112014015178A2 BR 112014015178 A2 BR112014015178 A2 BR 112014015178A2 BR 112014015178 A BR112014015178 A BR 112014015178A BR 112014015178 A BR112014015178 A BR 112014015178A BR 112014015178 A2 BR112014015178 A2 BR 112014015178A2
Authority
BR
Brazil
Prior art keywords
compound
Prior art date
Application number
BR112014015178A
Other languages
English (en)
Portuguese (pt)
Inventor
L Hancke Orozco Juan
Burgos Rafael
Original Assignee
Herbal Powers Corp
L Hancke Orozco Juan
Burgos Rafael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014015178(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Herbal Powers Corp, L Hancke Orozco Juan, Burgos Rafael filed Critical Herbal Powers Corp
Publication of BR112014015178A2 publication Critical patent/BR112014015178A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014015178A 2011-12-21 2012-12-19 uso de pelo menos um composto BR112014015178A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578650P 2011-12-21 2011-12-21
PCT/US2012/070568 WO2013096423A1 (en) 2011-12-21 2012-12-19 Combination therapy with interferon and andrographolides for multiple sclerosis

Publications (1)

Publication Number Publication Date
BR112014015178A2 true BR112014015178A2 (pt) 2017-06-13

Family

ID=48669439

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015178A BR112014015178A2 (pt) 2011-12-21 2012-12-19 uso de pelo menos um composto

Country Status (10)

Country Link
US (1) US9060994B2 (https=)
EP (1) EP2670406B1 (https=)
JP (1) JP5936707B2 (https=)
AU (1) AU2012359081B2 (https=)
BR (1) BR112014015178A2 (https=)
CA (1) CA2853779C (https=)
CL (1) CL2014001663A1 (https=)
ES (1) ES2554459T3 (https=)
RU (1) RU2014113967A (https=)
WO (1) WO2013096423A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3468553T3 (da) * 2016-06-08 2023-07-03 Innobioscience Llc Andrographolid behandler progressive former for multipel sklerose
US11318153B2 (en) 2018-06-25 2022-05-03 Bialpha International Sdn. Bhd. Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function
CN109824655B (zh) * 2019-04-08 2021-09-24 沈阳药科大学 穿心莲内酯化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
US6410590B1 (en) * 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
US20050181033A1 (en) 2000-06-29 2005-08-18 Dekker John P.Iii Method for delivering interferons to the intradermal compartment
AU2002326991A1 (en) * 2001-09-18 2003-04-01 Chiron Corporation Methods for treating multiple sclerosis
MXPA06008738A (es) * 2004-02-03 2008-03-07 Univ Austral De Chile Composicion que comprende una mezcla de lavadnos diterpenicos, de un extracto de planta andrographis paniculata, seleccionado de andrografolido, 14-deoxiandrografolido y neoandrografolido; sus usos.
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법

Also Published As

Publication number Publication date
RU2014113967A (ru) 2016-02-10
ES2554459T3 (es) 2015-12-21
CL2014001663A1 (es) 2015-02-27
WO2013096423A1 (en) 2013-06-27
AU2012359081A1 (en) 2014-06-05
CA2853779C (en) 2016-04-26
EP2670406B1 (en) 2015-09-02
NZ625051A (en) 2016-07-29
JP2015500880A (ja) 2015-01-08
AU2012359081B2 (en) 2015-09-17
US9060994B2 (en) 2015-06-23
JP5936707B2 (ja) 2016-06-22
US20140301981A1 (en) 2014-10-09
EP2670406A4 (en) 2014-05-28
EP2670406A1 (en) 2013-12-11
CA2853779A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
BR112016003454A2 (pt) Uso de composto de metil bardoxolona
BR112014000260A2 (pt) composto, e, uso de um composto
CO6900145A2 (es) Compuesto de ciclopropanoamina
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
LT2751083T (lt) Kvinolono junginys
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
EP2713762A4 (en) Stevia-COMPOSITION
BR112013029206A2 (pt) composto, e, uso de um composto
HRP20150709T8 (hr) Kompenzacijski spoj
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013023048A2 (pt) composto de guanidina
CO6930362A2 (es) Compuesto heterocíclico y su uso
BR112014023200A2 (pt) uso de uma composição
BR112014012016A2 (pt) compostos
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
CO6930368A2 (es) Composiciones de yodo-povidona estable
EP2693175A4 (en) MORE HEAD SCALE
DK2706977T3 (da) Dispergeringsmidler med biobaserede forbindelser
EP2786976A4 (en) MONOLITHIC COMPOSITION
BR112014016635A8 (pt) composto, composição, e, uso de um composto
LTC3246325I2 (lt) 2-acilaminotiazolo junginio kristalai
BR112014007641A2 (pt) uso de um biocida

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]